mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants.
Animals
Antibodies, Neutralizing
/ metabolism
Antibodies, Viral
/ metabolism
Antibody Affinity
BNT162 Vaccine
/ immunology
COVID-19
/ immunology
Cells, Cultured
Convalescence
Humans
Immunization, Secondary
Immunologic Memory
Mass Vaccination
Memory B Cells
/ immunology
Precursor Cells, B-Lymphoid
/ immunology
RNA, Messenger
/ genetics
SARS-CoV-2
/ genetics
Spike Glycoprotein, Coronavirus
/ immunology
B-cell memory
BNT162b2 vaccine
COVID-19
RBD
affinity maturation
germinal center
neutralizing antibody
plasma cells
somatic hypermutation
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
14 12 2021
14 12 2021
Historique:
received:
17
06
2021
revised:
05
08
2021
accepted:
14
09
2021
pubmed:
7
10
2021
medline:
24
12
2021
entrez:
6
10
2021
Statut:
ppublish
Résumé
In addition to serum immunoglobulins, memory B cell (MBC) generation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is another layer of immune protection, but the quality of MBC responses in naive and coronavirus disease 2019 (COVID-19)-recovered individuals after vaccination remains ill defined. We studied longitudinal cohorts of naive and disease-recovered individuals for up to 2 months after SARS-CoV-2 mRNA vaccination. We assessed the quality of the memory response by analysis of antibody repertoires, affinity, and neutralization against variants of concern (VOCs) using unbiased cultures of 2,452 MBCs. Upon boosting, the MBC pool of recovered individuals expanded selectively, matured further, and harbored potent neutralizers against VOCs. Although naive individuals had weaker neutralizing serum responses, half of their RBD-specific MBCs displayed high affinity toward multiple VOCs, including delta (B.1.617.2), and one-third retained neutralizing potency against beta (B.1.351). Our data suggest that an additional challenge in naive vaccinees could recall such affinity-matured MBCs and allow them to respond efficiently to VOCs.
Identifiants
pubmed: 34614412
pii: S1074-7613(21)00396-4
doi: 10.1016/j.immuni.2021.09.011
pmc: PMC8452492
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
RNA, Messenger
0
Spike Glycoprotein, Coronavirus
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2893-2907.e5Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of interests Outside of the submitted work, M. Mahévas. received research funds from GSK and personal fees from LFB and Amgen. J.-C.W. received consulting fees from Institut Mérieux. P.B. received consulting fees from Regeneron Pharmaceuticals. J.-M.P. received personal fees from Abbvie, Gilead, Merck, and Siemens Healthcare. F.R. is a member of the board of MELETIOS Therapeutics and of the Scientific Advisory Board of eureKARE.
Références
N Engl J Med. 2021 Jun 10;384(23):2212-2218
pubmed: 33882219
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
Bioinformatics. 2015 Oct 15;31(20):3356-8
pubmed: 26069265
Cell. 2021 Jun 10;184(12):3205-3221.e24
pubmed: 34015271
Sci Transl Med. 2015 Dec 2;7(316):316ra192
pubmed: 26631631
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Science. 2021 Aug 13;373(6556):818-823
pubmed: 34016740
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
Immunity. 2021 Jun 8;54(6):1290-1303.e7
pubmed: 34022127
Nature. 2021 Dec;600(7889):517-522
pubmed: 34619745
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Science. 2021 Apr 30;:
pubmed: 33931567
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Sci Immunol. 2021 Feb 23;6(56):
pubmed: 33622975
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Blood. 2009 Feb 12;113(7):1422-31
pubmed: 19059876
Sci Transl Med. 2021 Apr 14;13(589):
pubmed: 33853929
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Cell Host Microbe. 2021 Apr 14;29(4):516-521.e3
pubmed: 33798491
Nat Immunol. 2020 Dec;21(12):1506-1516
pubmed: 33028979
Microorganisms. 2021 Jul 20;9(7):
pubmed: 34361977
Cell. 2020 Jan 9;180(1):92-106.e11
pubmed: 31866068
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
Science. 2020 Sep 25;369(6511):1586-1592
pubmed: 32694201
J Exp Med. 2011 Dec 19;208(13):2599-606
pubmed: 22162833
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Cell Rep Med. 2021 Apr 20;2(4):100255
pubmed: 33842902
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Cell. 2021 Mar 4;184(5):1201-1213.e14
pubmed: 33571429
Cell Host Microbe. 2021 Jan 13;29(1):23-31.e4
pubmed: 33306985
Cell. 2020 Oct 29;183(3):739-751.e8
pubmed: 32991842
J Clin Med. 2021 Jun 27;10(13):
pubmed: 34199029
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
Nat Commun. 2021 Jul 7;12(1):4196
pubmed: 34234131
Science. 2021 Mar 25;:
pubmed: 33766944
Nat Immunol. 2016 Oct;17(10):1226-34
pubmed: 27525369
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Immunity. 2016 Jan 19;44(1):116-130
pubmed: 26795247
Sci Transl Med. 2022 Feb 09;14(631):eabi8961
pubmed: 34874183
J Biomol Screen. 2015 Apr;20(4):498-507
pubmed: 25425568
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Cell. 2021 Sep 16;184(19):4969-4980.e15
pubmed: 34332650